Across TCGA pan-cancer cohorts, GIGYF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GIGYF2 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GIGYF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GIGYF2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

HNSC, ACC, and LGG are the cancer types where GIGYF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.156	0.673	.024	12	view →
ACC	DFS	Median	All	0.210	0.766	<.001	9	view →
LGG	OS	Median	All	0.195	0.889	<.001	7	view →
COAD	OS	Median	All	1.000	0.861	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GIGYF2 tumor-vs-normal RNA expression · all GIGYF2 data types